ArticleslgStudy

chemistry

Sofosbuvir/daclatasvir

Sofosbuvir/daclatasvir is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Sofosbuvir/daclatasvir rather than just read about it. In short: Daclatasvir/sofosbuvir (trade names Darvoni, Sovodak) is a two-drug combination for the treatment of hepatitis C. It is given as a single daily pill containing daclatasvir, a viral NS5A inhibitor, and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase NS5B.

Sofosbuvir/daclatasvir — main illustration
Sofosbuvir/daclatasvir — illustration

Key takeaways

  • Sofosbuvir/daclatasvir belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Sofosbuvir/daclatasvir to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Sofosbuvir/daclatasvir from memory before moving on to harder problems.

Reference excerpt

Daclatasvir/sofosbuvir (trade names Darvoni, Sovodak) is a two-drug combination for the treatment of hepatitis C. It is given as a single daily pill containing daclatasvir, a viral NS5A inhibitor, and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase NS5B. It is on the World Health Organization's List of Essential Medicines.

Society and culture This combination is produced by an Iranian company under the trade name of Sovodak. The combination includes 400 mg sofosbuvir and 60 mg daclatasvir and has been used in clinical trials since 2015. Sovodak was approved by the Iranian Food and Drug Administration in October 2015 and is currently marketed in Iran as the treatment of choice for all genotypes of hepatitis C as recommended by the national Iranian guideline for treating hepatitis C.

Research The similarities between the hepatitis C and SARS-CoV-2 virus has led some researches to investigate the effectiveness of sofosbuvir/daclatasvir against COVID-19. Three recently published studies have found this combination to be beneficial against COVID-19 although the findings require confirmation by larger studies. In October 2020, a meta-analysis found a significantly lower risk of all-cause mortality with the drug combination when given to hospitalized patients with COVID-19.

References

Illustrations

Sofosbuvir/daclatasvir illustration

Worked examples

Example 1 — a first encounter with Sofosbuvir/daclatasvir

Start with the simplest possible case. Write down what Sofosbuvir/daclatasvir claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Sofosbuvir/daclatasvir before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Sofosbuvir/daclatasvir ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Sofosbuvir/daclatasvir

In research
Sofosbuvir/daclatasvir appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Sofosbuvir/daclatasvir in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Sofosbuvir/daclatasvir is common in secondary-school and first-year university syllabi. It links to neighbouring topics Anti-infective agent stubs, Combination antiviral drugs, NS5A inhibitors, so understanding it makes those chapters shorter.
In everyday life
Look for Sofosbuvir/daclatasvir outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Sofosbuvir/daclatasvir” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Sofosbuvir/daclatasvir in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Sofosbuvir/daclatasvir means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Sofosbuvir/daclatasvir out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Sofosbuvir/daclatasvir in simple terms?

Daclatasvir/sofosbuvir (trade names Darvoni, Sovodak) is a two-drug combination for the treatment of hepatitis C. It is given as a single daily pill containing daclatasvir, a viral NS5A inhibitor, and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase NS5B.

Why does Sofosbuvir/daclatasvir matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Sofosbuvir/daclatasvir?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Sofosbuvir/daclatasvir.

Tags

  • Anti-infective agent stubs
  • Combination antiviral drugs
  • NS5A inhibitors
  • NS5B (polymerase) inhibitors
  • World Health Organization essential medicines

Keep exploring